# Adia Nutrition, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Adia Nutrition, Inc.).

## Overview

Adia Nutrition, Inc. is a U.S.-based healthcare and nutrition company organized around operating subsidiaries that provide medical procedures, biologic products, and related ancillary services. Its business is centered in the United States and is structured through entities including Adia Med, Adia Labs, and Biolete, LLC.

## Products & services

• Medical procedures
• Biologic products
• Ancillary products
• Shipping and delivery services
• Supplement sales

- **Medical procedures** (60%) — Clinical procedures and related patient services performed through the Adia Med business.
- **Biologic products** (35%) — Sales of biologic products recognized net of discounts and refunds.
- **Ancillary products and supplements** (3%) — Smaller product sales tied to the company’s healthcare and nutrition offering.
- **Shipping and delivery** (2%) — Fulfillment and delivery charges associated with product sales.

- Medical procedures
- Biologic products
- Ancillary products
- Shipping and delivery services
- Supplement sales

## Customers

The company serves U.S. customers that purchase medical procedures directly through its healthcare operations and customers that buy biologic products and related ancillary items. Its revenue mix suggests a combination of patient-facing demand and product-based demand tied to the company’s clinical and wellness offerings.

- **Medical procedure patients** (primary) — Individuals purchasing procedures from Adia Med for direct clinical services.
- **Biologic product customers** (primary) — Customers buying biologic products sold through the company’s product channel.
- **Supplement and ancillary product buyers** (secondary) — Customers purchasing smaller nutrition or support products alongside core services.
- **Shipping and fulfillment customers** (emerging) — Customers whose orders include delivery charges and logistics services.

- Patients seeking medical procedures through Adia Med
- Customers buying biologic products
- Buyers of ancillary wellness or support products
- Supplement customers in the company’s nutrition channel
- Customers needing shipping and delivery tied to orders

## Geography

The company reports that it has no operations or sources of revenue outside the United States, so its business is concentrated in one market. This makes performance dependent on U.S. healthcare demand, domestic regulation, and U.S.-based operating infrastructure.

- **United States** (100%) — Company states it has no operations or sources of revenue outside the United States.

- All revenue is generated in the United States
- No disclosed operations outside the U.S.
- Domestic concentration ties results to U.S. healthcare demand
- U.S. regulation and reimbursement environment matter materially

## Strategy

Adia Nutrition’s stated direction is to grow revenue by expanding its medical and biologic offerings while using available funding sources to support working capital and receivables. The company also relies on capital raising and credit facilities to fund continued operations and growth initiatives.

- **Expand revenue from core healthcare and biologic offerings** (short-term) — The business depends on increasing sales volume across procedures and product channels.
- **Secure funding for working capital and growth** (short-term) — The company needs external capital to support operations, receivables, and expansion.

- Grow revenue from medical procedures and biologic products
- Use line of credit capacity for bridge and operating capital
- Pursue external financing to support expansion
- Maintain multiple operating subsidiaries for product and service lines

## Risks

The company faces going-concern and financing risk because it depends on continued access to capital and higher revenue to support operations. It is also exposed to execution risk in a small, U.S.-only healthcare and biologics business where demand, regulation, and product economics can change quickly.

- **Going-concern uncertainty** [critical] — The company states it needs higher revenue and third-party capital to continue as a going concern.
- **Dependence on external financing** [high] — Growth and working capital rely on a line of credit and capital raises.
- **Related-party dependence** [medium] — The company leases office space from and receives working capital support from an entity controlled by the CEO and director.
- **U.S. market concentration** [medium] — All revenue is generated in the United States, increasing exposure to domestic demand and regulation.

- Going-concern risk if revenue and financing do not improve
- Dependence on related-party funding and credit support
- Concentration in the U.S. healthcare market
- Revenue volatility across procedures and product sales
- Regulatory and compliance risk in medical and biologic offerings

## Accounting

Revenue is recognized under ASC 606 when control of goods or services transfers, which matters because the company has multiple revenue streams including procedures, biologics, shipping, and other services. Management also relies on estimates, fair value judgments, and impairment testing for long-lived assets, while related-party arrangements and segment allocations affect how results are presented.

- **Revenue recognition under ASC 606** — Can affect timing and comparability of quarterly revenue
- **Use of estimates** — Can materially affect reported results if assumptions change
- **Long-lived asset impairment** — May create non-cash charges if asset values are not recoverable
- **Related-party transactions** — Affects expense classification, disclosure, and financing terms

- ASC 606 timing affects procedure and product revenue recognition
- Revenue mix includes goods, services, shipping, and ancillary items
- Management estimates affect reported assets, liabilities, and expenses
- Long-lived asset impairment could affect carrying values
- Related-party leases and credit facilities affect disclosures and costs

---

*Last updated: 2026-08-11T04:46:19.510904+00:00*